Pressure BioSciences Announces Contracted Production Launch for Estimated $3,000,000 of UST-Processed, Nanoemulsified CBD Spray for Oral Use
Safer Medical of Montana, a Seasoned Distributor of Wellness Products with a Focus on Veterans, Partners with PBI as Exclusive Distributor for Highly Stable and Water-Soluble CBD Oral Aerosol Product
SOUTH EASTON, MA / ACCESSWIRE / June 29, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmetics, agrochem, and food/beverage industries, today announced its signed agreement with Safer Medical of Montana (“SMM”) on production, distribution, commercial roll-out and financial partnership for a novel, effectively water-soluble, nanoemulsified CBD spray for oral use. SMM’s roll-out and distribution plan targets revenues of $3M or more over the first 12-months post-release. Under the agreement, PBI expects to realize more than $1M in revenues from this $3M product sales target. This is the first commercial product being produced and marketed that incorporates the Company’s patented Ultra Shear Technology™ (UST™) platform.
As announced last month, PBI and SMM have collaborated over the past year in the development of a proprietary formulation for this unique product. The companies have now completed formulation development and are securing the necessary approvals for production in the Commonwealth of Massachusetts and distribution throughout all of the United States. SMM’s initial product will be an oral spray containing 40mg/mL of nanoemulsified CBD. The companies plan to release the new CBD oral spray product to consumers during the third quarter of 2022.
Mr. John B. Hollister, Director of Sales and Marketing at PBI, observed: “This SMM agreement launches an exciting new chapter in the evolution of PBI. Building on our deep expertise in the safe applications of high-pressure technology, we are now preparing to release the first product prepared by UST – our truly revolutionary platform technology that shears oil-water emulsions down to extremely low and tightly-controlled nano-sized oil droplets. The commercialization of UST throws open the door to countless applications in diverse multi-billion-dollar markets where effective water-solubility of oil-based active ingredients is critical for optimized bioavailability and absorption – including cannabinoids, nutraceuticals, cosmetics, pharmaceuticals, food and beverages, agrochem, industrial lubricants, paints, and more.”
Mr. Hollister continued: “The feedback we have received across many sample products created with UST has exceeded all expectations. The application of UST to provide greatly improved delivery and functionality of oil-based active materials and products via nanoemulsification offers enormous potential to translate into a diverse array of major commercial opportunities for our partners and for PBI, while benefitting and redefining product expectations for consumers worldwide.”
Captain George Ackerson, Founder and CEO of SMM, shared his plans: “With this partnership and distribution agreement in place, our mission is now on the successful launch of the nanoemulsified CBD oral spray. This launch includes a key focus on accessing U.S. veterans, a group we believe will benefit greatly from this innovative product. We are reaching out to the Veterans Administration and developing plans to work with the not-for-profit Veteran Seal Team, Inc. (“VST”). In addition to direct sales through our website, we are setting up distribution with a network of nurses who specialize in the needs of veterans.”
Captain Ackerson continued: “SMM has been distributing wellness products for many years, giving us significant experience in the best ways to get novel, breakthrough products into the hands of consumers. The PBI partnership is built upon estimated first-year sales of over $3 million dollars, to be achieved through three planned phases of roll-out at increasing scale. With our current and planned distribution channels, we believe this goal is more than attainable.”
Mr. Richard T. Schumacher, President and CEO of PBI, summed up: “This first UST commercialization and partnering agreement with Captain Ackerson and Safer Medical of Montana is a pivotal transition moment in the history of PBI. We are expecting to announce significant additional agreements in the very near future, specifically in markets with an expected quick ramp to revenue, such as cosmetics, agrochem, and nutraceuticals. We also believe that our co-leadership role in the Food Industry Consortium with partner The Ohio State University, whose mission is to introduce the UST platform to food and beverage companies worldwide, will soon result in additional revenue-generating agreements. We expect that the substantial revenue expected from these future agreements will accelerate balance sheet improvements and help finance PBI’s operations, investments, growth, and trajectory to profitability before the end of 2023.”
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.
Forward Looking Statements
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.
For more information about PBI and this press release, please click on the following website link:
http://www.pressurebiosciences.com
Please visit us on Facebook, LinkedIn, and Twitter.
Press Contacts:
Richard T. Schumacher, President & CEO (508) 230-1828 (T)
John B. Hollister, Director of Sales and Marketing (805) 908-5719 (T)
Jeffrey N. Peterson, Chairman (650)703-8557 (T)
SOURCE: Pressure BioSciences Inc.
View source version on accesswire.com:
https://www.accesswire.com/706907/Pressure-BioSciences-Announces-Contracted-Production-Launch-for-Estimated-3000000-of-UST-Processed-Nanoemulsified-CBD-Spray-for-Oral-Use
